ROCKVILLE, MD, November 13, 2009 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.
“Emergent is excited about this new facility in Baltimore because it houses several suites capable of manufacturing multiple products at the same time,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “Accordingly, this facility will provide the flexibility to conduct large-scale manufacturing of rPA while also producing other products in our pipeline.”
Emergent worked closely with the Maryland Department of Business and Economic Development (DBED), MdBio, the City of Baltimore, Baltimore Development Corporation, and other related governmental agencies to complete this transaction.
“Maryland is continuing to strengthen its biotechnology prowess by helping to grow industry leaders like Emergent BioSolutions,” said Governor Martin O’Malley. “The transaction between MdBio and Emergent will maximize the value of the BioProcessing Center by maintaining a bio-manufacturing infrastructure for Maryland’s bioscience community, enabling additional investment to be made in the Center and ensuring that those high paying, highly skilled jobs are created and remain in Maryland.”
Emergent BioSolutions employs over 600 employees across the globe, with over 150 employees located in its corporate headquarters in Rockville and one of its product development sites in Gaithersburg.
“This acquisition reflects our commitment to both continually creating jobs and investing additional capital in the State of Maryland,” said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. “We extend our sincere appreciation to the state and local governments for their ongoing support of our efforts to develop our local manufacturing capabilities and look forward to growing Emergent’s presence in the state.”
Mayor Sheila Dixon, commenting on the announcement, said, “The City of Baltimore is excited about welcoming Emergent BioSolutions to the Baltimore biotech community. With great research institutions such as Johns Hopkins and the University of Maryland as potential partners in the area, we know that Emergent will be a wonderful contributor in the future.”
“Emergent’s decision to expand in Maryland underscores not only our rich research and development environment, but also our mission to support the complete product development life cycle that includes bio manufacturing,” said Maryland Department of Business and Economic Development Secretary Christian S. Johansson. “The Department was pleased to work with MdBio Foundation and the Baltimore Development Corp. to bring this project to fruition.”
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com and www.biothrax.com.
About MdBio Foundation, Inc.
The MdBio Foundation, Inc. is a charitable and educational organization whose mission is to provide and support the State of Maryland’s bioscience community through bioscience awareness, education and workforce development programs including scholarships, post-doctoral conference and career expos, BioGENEius science competition and summer science camps. Since 2003, MdBio has operated the MdBioLab, an educational and well-known mobile bioscience laboratory that visits high schools throughout Maryland to educate youth on biosciences. Over the past six years, MdBioLab has held more than 2,800 classes with 55,000 students and 1,500 teachers. MdBio Foundation became an affiliate of the Tech Council of Maryland in 2006.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2009, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including our ability to obtain FDA approval to manufacture products or product candidates in the newly acquired facility; appropriations for BioThrax® procurement; our ability to obtain new BioThrax® sales contracts; our plans to pursue label expansions and improvements for BioThrax®; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the period ended September 30, 2009 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
###
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=cd1e42ac-b4c7-4295-bf36-8d6531186487)
When someone develops an infection at a hospital or other patient care facility that they did not have prior to treatment, this is referred to as a healthcare-associated (sometimes hospital-acquired) infection (
Ventilator - Associated Pneumonia (VAP)
Surgical Site Infections (SSIs)
Cross Contamination (Contact Transfer)
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=758247b1-07fb-4219-8091-3cf260fe2267)
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=34a3b599-2852-4cc7-b589-1da959bf9c64)
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=77d50a38-dd4d-4df9-988c-e33af58473d0)
